LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

Search

Intuitive Surgical Inc

Slēgts

SektorsVeselības aprūpe

500.19 0.64

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

491.06

Max

505.23

Galvenie mērījumi

By Trading Economics

Ienākumi

90M

800M

Pārdošana

361M

2.9B

P/E

Sektora vidējais

62.896

66.845

Peļņas marža

27.894

Darbinieki

17,021

EBITDA

70M

1.1B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+30.18% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 21. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-16B

176B

Iepriekšējā atvēršanas cena

499.55

Iepriekšējā slēgšanas cena

500.19

Ziņu noskaņojums

By Acuity

22%

78%

51 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Intuitive Surgical Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 21. okt. 23:55 UTC

Karstas akcijas

Stocks to Watch: DraftKings, Texas Instruments, Intuitive Surgical, Pegasystems

2025. g. 21. okt. 21:14 UTC

Peļņas
Galvenie tirgus virzītāji

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth -- Update

2025. g. 21. okt. 20:38 UTC

Peļņas

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth

2025. g. 22. jūl. 21:13 UTC

Peļņas

Intuitive Surgical Logs Higher Profit, Revenue in 2Q

2026. g. 17. febr. 14:48 UTC

Peļņas

Medtronic Posts Better-Than-Expected Earnings. Here's Why the Stock Is Falling. -- Barrons.com

2026. g. 23. janv. 16:07 UTC

Peļņas

Intuitive Surgical Stock Beats Earnings Estimates. The Stock Is Barely Moving. -- Barrons.com

2026. g. 23. janv. 12:58 UTC

Peļņas

Intuitive Surgical Stock Rises on Earnings. What Wall Street Is Saying. -- Barrons.com

2026. g. 22. janv. 21:11 UTC

Peļņas

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

2026. g. 22. janv. 21:11 UTC

Peļņas

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

2026. g. 22. janv. 21:10 UTC

Peļņas

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

2026. g. 22. janv. 21:05 UTC

Peļņas

Intuitive Surgical 4Q EPS $2.21 >ISRG

2026. g. 22. janv. 21:05 UTC

Peļņas

Intuitive Surgical 4Q Rev $2.87B >ISRG

2026. g. 22. janv. 21:05 UTC

Peļņas

Intuitive Surgical 4Q Net $794.8M >ISRG

2026. g. 22. janv. 21:05 UTC

Peļņas

Intuitive Surgical 4Q Adj EPS $2.53 >ISRG

2026. g. 22. janv. 21:05 UTC

Peļņas

Intuitive Surgical 4Q Da Vinci Surgical Systems Shipped 532.00 >ISRG

2025. g. 30. okt. 12:38 UTC

Peļņas

Looking to Diversify Out of the AI Trade? Buy Boston Scientific Stock. -- Barrons.com

2025. g. 30. okt. 12:01 UTC

Peļņas

Looking to Diversify Out of the AI Trade? Buy Boston Scientific Stock. -- Barrons.com

2025. g. 22. okt. 15:42 UTC

Peļņas

Intuitive Surgical Stock Jumps on Earnings. Its Newest Surgical Robot Is Going Gangbusters. -- Barrons.com

2025. g. 22. okt. 12:34 UTC

Peļņas

Intuitive Surgical Stock Surges. Earnings Show It Can Maintain 'Bellwether Medtech Growth Status.' -- Barrons.com

2025. g. 22. okt. 11:49 UTC

Peļņas

Intuitive Surgical Stock Surges. Earnings Show It Can Maintain 'Bellwether Medtech Growth Status.' -- Barrons.com

2025. g. 21. okt. 20:08 UTC

Peļņas

Intuitive Surgical: Worldwide Da Vinci Procedure Growth of Approximately 17% to 17.5% in 2025, Compared to 17% in 2024 >ISRG

2025. g. 21. okt. 20:08 UTC

Peļņas

Intuitive Surgical: Non-GAAP Gross Profit Margin to Be Within a Range of 67% and 67.5% of Rev in 2025, Compared to 69.1% in 2024 >ISRG

2025. g. 21. okt. 20:05 UTC

Peļņas

Intuitive Surgical 3Q Rev $2.51B >ISRG

2025. g. 21. okt. 20:05 UTC

Peļņas

Intuitive Surgical 3Q Net $704.4M >ISRG

2025. g. 21. okt. 20:05 UTC

Peļņas

Intuitive Surgical 3Q Adj EPS $2.40 >ISRG

2025. g. 21. okt. 20:05 UTC

Peļņas

Intuitive Surgical 3Q Da Vinci Surgical Systems Shipped 427.00 >ISRG

2025. g. 21. okt. 20:05 UTC

Peļņas

Intuitive Surgical 3Q EPS $1.95 >ISRG

2025. g. 22. jūl. 20:14 UTC

Peļņas

Intuitive Surgical Sees FY25 Non-GAAP Gross Profit Margin to Be Within Range of 66% and 67% >ISRG

2025. g. 22. jūl. 20:13 UTC

Peļņas

Intuitive Surgical Sees FY25 Worldwide Da Vinci Procedure Growth of 15.5% to 17% >ISRG

2025. g. 22. jūl. 20:13 UTC

Peļņas

Intuitive Surgical Grew Da Vinci Surgical System Installed Base to 10,488 Systems as of June 30 >ISRG

Salīdzinājums

Cenas izmaiņa

Intuitive Surgical Inc Prognoze

Cenas mērķis

By TipRanks

30.18% augšup

Prognoze 12 mēnešiem

Vidējais 647.56 USD  30.18%

Augstākais 750 USD

Zemākais 550 USD

Pamatojoties uz 19 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Intuitive Surgical Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

19 ratings

14

Pirkt

5

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

514.59 / 539.05Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

Weak Bullish Evidence

Ilgtermiņā

Strong Bullish Evidence

Noskaņojums

By Acuity

51 / 351 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Intuitive Surgical Inc

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
help-icon Live chat